Michael Barbella, Managing Editor09.22.23
Anika Therapeutics launched its RevoMotion Reverse Shoulder Arthroplasty System (RSA) this week at the 2023 Orthopaedic Summit (OSET) Annual Meeting in Boston. RevoMotion expands the company’s shoulder arthroplasty portfolio and provides a bone conserving and innovative solution in the $1 billion1 U.S. reverse shoulder market.
“We’re excited to showcase our breakthrough new products focused on early intervention orthopedics, including the launch of our RevoMotion Reverse Shoulder Arthroplasty System, designed specifically to address clinical needs through a truly bone preserving design with simple and efficient instrumentation,” Anika President/CEO Cheryl R. Blanchard, Ph.D., said. “We are also thrilled to preview at OSET our recently cleared Integrity regenerative HA-based rotator cuff patch system, which is uniquely strong, versatile, and easy-to-use. Integrity has an innovative delivery and fixation system and has greater regenerative capacity compared to first generation collagen patches. Anika’s shoulder portfolio, which also includes our recently launched X-Twist suture anchors, Tactoset HA-enhanced injectable bone substitute cleared for hardware augmentation, and OVOMotion with Inlay Glenoid Total Shoulder Arthroplasty, is further reinforced by the full market launch of RevoMotion. Based on the very positive surgeon feedback during our successful limited market release, we are confident that RevoMotion and our expanding rotator cuff portfolio meaningfully enhances the value that we can provide to surgeons and their patients in both the ASC and hospital settings.”
Key benefits of RevoMotion include:
Additionally, Anika showcased its other products at the OSET meeting, such as the OVOMotion with Inlay Glenoid TSA System, the only system that offers a true Inlay Glenoid, with data demonstrating that inset performance does not equal inlay; X-Twist Fixation System; and Tactoset Injectable Bone Substitute, which is indicated for both hardware augmentation and use with Bone Marrow Aspiration (BMA).
Anika also demonstrated at OSET the Integrity Implant System, a regenerative hyaluronic acid-based patch system for augmentation of rotator cuff repairs that is comprised of the HA-based patch implant, fixation implants, and single-use arthroscopic delivery instruments. In a pre-clinical head-to-head animal study, Integrity demonstrated greater regenerative capacity at both 12- and 26-week endpoints.2 Additionally, Integrity is inherently strong and can be confidently manipulated arthroscopically, which offers a unique and differentiated solution. The Integrity Implant System was cleared by the U.S. Food and Drug Administration in August 2023 and will formally be launched in Q1 2024.
“I’m excited to see Anika working to improve the biologic augmentation market starting with rotator cuff repair. While some collagen products on the market are showing promising results with biological incorporation, in animal studies, Integrity facilitated improved biological healing without the use of animal collagen, while also providing a scaffold that can add strength to the construct at the time of implantation," Baker said. "In addition to improving the patch itself, they have also identified a more streamlined surgical technique. This product could improve patient outcomes and reduce the likelihood of future failures of rotator cuff repair.”
Anika Therapeutics is a global joint preservation company that partners with clinicians to provide minimally invasive products that restore active living for people worldwide. Its focus is on high opportunity spaces within orthopedics, including osteoarthritis pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions, and products are delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston.
References
1 2023E SmartTRAK Data
2 Data on file
“We’re excited to showcase our breakthrough new products focused on early intervention orthopedics, including the launch of our RevoMotion Reverse Shoulder Arthroplasty System, designed specifically to address clinical needs through a truly bone preserving design with simple and efficient instrumentation,” Anika President/CEO Cheryl R. Blanchard, Ph.D., said. “We are also thrilled to preview at OSET our recently cleared Integrity regenerative HA-based rotator cuff patch system, which is uniquely strong, versatile, and easy-to-use. Integrity has an innovative delivery and fixation system and has greater regenerative capacity compared to first generation collagen patches. Anika’s shoulder portfolio, which also includes our recently launched X-Twist suture anchors, Tactoset HA-enhanced injectable bone substitute cleared for hardware augmentation, and OVOMotion with Inlay Glenoid Total Shoulder Arthroplasty, is further reinforced by the full market launch of RevoMotion. Based on the very positive surgeon feedback during our successful limited market release, we are confident that RevoMotion and our expanding rotator cuff portfolio meaningfully enhances the value that we can provide to surgeons and their patients in both the ASC and hospital settings.”
Key benefits of RevoMotion include:
- Industry’s smallest diameter threaded glenoid baseplate: RevoMotion features the industry’s smallest diameter threaded baseplate,2 which preserves bone, provides flexibility in positioning, and maximizes fixation of the glenoid components, all while achieving substantial fixation via a central compression screw.
- Mid-lay Humeral Implant: Partially in-lay and partially on-lay, with seven humeral tray sizes providing a more precise fit and are designed for optimal range of motion and reduced risk of scapular notching. The humeral tray and bone preparation are designed to decrease stress shielding on the proximal humerus with forces evenly distributed across entire proximal humerus.
- Bone preservation and patient personalization: The system includes bone preserving glenoid and humeral designs intended to provide patient personalization via numerous humeral tray offerings which match the native anatomy, similar to other implant system designs in Anika’s Arthrosurface Joint Solutions portfolio including the flagship OVOMotion with Inlay Glenoid Total Shoulder Arthroplasty System.
- Enhanced efficiency for surgeons and facilities: With its two streamlined instrument trays, RevoMotion appeals to both surgeons and facilities looking to optimize efficiency. The consolidated instrumentation is both Ambulatory Surgery Center (ASC) and hospital friendly, reducing back table footprint, limiting sterile reprocessing, and reducing relative costs associated with more complex designs currently on the market.
Additionally, Anika showcased its other products at the OSET meeting, such as the OVOMotion with Inlay Glenoid TSA System, the only system that offers a true Inlay Glenoid, with data demonstrating that inset performance does not equal inlay; X-Twist Fixation System; and Tactoset Injectable Bone Substitute, which is indicated for both hardware augmentation and use with Bone Marrow Aspiration (BMA).
Anika also demonstrated at OSET the Integrity Implant System, a regenerative hyaluronic acid-based patch system for augmentation of rotator cuff repairs that is comprised of the HA-based patch implant, fixation implants, and single-use arthroscopic delivery instruments. In a pre-clinical head-to-head animal study, Integrity demonstrated greater regenerative capacity at both 12- and 26-week endpoints.2 Additionally, Integrity is inherently strong and can be confidently manipulated arthroscopically, which offers a unique and differentiated solution. The Integrity Implant System was cleared by the U.S. Food and Drug Administration in August 2023 and will formally be launched in Q1 2024.
“I’m excited to see Anika working to improve the biologic augmentation market starting with rotator cuff repair. While some collagen products on the market are showing promising results with biological incorporation, in animal studies, Integrity facilitated improved biological healing without the use of animal collagen, while also providing a scaffold that can add strength to the construct at the time of implantation," Baker said. "In addition to improving the patch itself, they have also identified a more streamlined surgical technique. This product could improve patient outcomes and reduce the likelihood of future failures of rotator cuff repair.”
Anika Therapeutics is a global joint preservation company that partners with clinicians to provide minimally invasive products that restore active living for people worldwide. Its focus is on high opportunity spaces within orthopedics, including osteoarthritis pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions, and products are delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston.
References
1 2023E SmartTRAK Data
2 Data on file